Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 379 Publications

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 M3fLeGN6fG:2b4jpZ{BCe3OjeR?= Mmq0OVAh|ryP M1vrcVQ5KGh? MWjEUXNQ NUixfWZ4U2mubIOgZ4VtdHNiYomgcY9z\SC2aHHuJFk6LQ>? NVroc2FzOTB2OUm2OFM>
OVCA 429 M1ewbWZ2dmO2aX;uJGF{e2G7 M4fSTVMxOCCwTR?= NVXEbHFHPDhiaB?= MYHEUXNQ NGHR[Y5FcXO{dYD0d{BqdnSjY4SgcZVtfGmlZXzseYxieiC2dX3vdkB{eGincn;p[JM> M2q5e|ExQTl7N{[2
RPMI8226 M1\CcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXGzSmpQOTByIH7N M{XIcVQ5KGh? NWPNb5c2TE2VTx?= MU\JR|UxRTNyIH7N MnzxNVE{ODZ2OEm=
Dox40 NWHIUnNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUmxNFAhdk1? NX;VNHY6PDhiaB?= NHfTWHRFVVOR MlzTTWM2OD12MDDuUS=> M3jBXlEyOzB4NEi5
MR20 MkLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmOzNVAxKG6P Mlz4OFghcA>? M4jBRWROW09? M2W5bmlEPTB;MkCgcm0> MXOxNVMxPjR6OR?=
LR5 NIj0RYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnv6NVAxKG6P NF:xOZQ1QCCq MoTjSG1UVw>? MonkTWM2OD1{MDDuUS=> NX;GO5lmOTF|ME[0PFk>
U266 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPhdVNVOTByIH7N NYnUfWFnPDhiaB?= M2jWNmROW09? M3j3e2lEPTB;MzDuUS=> M3TYRVEyOzB4NEi5
IM-9 M3vvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFO3VHoyODBibl2= M{jSNlQ5KGh? MVnEUXNQ MkXGTWM2OD14IH7N MkDCNVE{ODZ2OEm=
Hs Sultan NW\Ieok{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGKybmwyODBibl2= NILTPY41QCCq NIHpPZpFVVOR MnrZTWM2OD1{MDDuUS=> NVz2eJR3OTF|ME[0PFk>
PAM-LY2 MWXGeY5kfGmxbjDBd5NigQ>? MU[xNFAhdk1? NGTvWXYyOiCq MV7EUXNQ Mn;TTY5pcWKrdIOgUmYu|rqEIHHjeIl3[XSrb36= MYWxNVM2ODlzMx?=
PAM 212 MomxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVyxNFAhdk1? MlrHO|IhcA>? NHfxWJhFVVOR NWnyUGlMUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= MVexNVM2ODlzMx?=
PAM-LY2 NH73VphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PlU|ExOCCwTR?= MmXaO|IhcA>? M1rF[WROW09? Mo\HTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MWOxNVM2ODlzMx?=
B4B8 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[xNFAhdk1? NWjBS41SPzJiaB?= M4X5fWROW09? Mk\vTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MmG4NVE{PTB7MUO=
B7E3 M4TnTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LWdlExOCCwTR?= Mn3LO|IhcA>? Ml3qSG1UVw>? M{DafGlvcGmkaYTzJINmdGxidnnhZoltcXS7 NGLIdWQyOTN3MEmxNy=>
UM-SCC-9 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXXWXNLOTByIH7N NWnpdoFCPzJiaB?= NFjoNmdFVVOR M361eGlvcGmkaYTzJINmdGxidnnhZoltcXS7 M3vGVVEyOzVyOUGz
UM-SCC-11B M{XnbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX1cJRFOTByIH7N M3fSflczKGh? Ml3GSG1UVw>? M3T2U2lvcGmkaYTzJINmdGxidnnhZoltcXS7 NWXnR4pUOTF|NUC5NVM>
H460 MoHPSpVv[3Srb36gRZN{[Xl? NH\leo8yOCEQvF2= NY\MXWpPOjRiaB?= MYnEUXNQ M4W0bWlv\HWlZYOgRoNtNTJicHjvd5Bpd3K7bHH0bY9vKGGwZDDjcIVifmGpZTDjc5Jz\WyjdHXkJJdqfGhiR{KtUUBxcGG|ZTDhdpJme3R? NXzHWpd6OTJ2OUKxNVc>
U266 NE\tdYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYe1NFAhdmdxbXy= M3HJRlQ5KGh? NXTqdoZzTE2VTx?= MUXJcohq[mm2czDj[YxtKGe{b4f0bC=> Mmf6NVI3OzF4MUm=
ARH77 NF7mRVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LCV|UxOCCwZz;tcC=> NIHKNHo1QCCq MV7EUXNQ M{jXNmlvcGmkaYTzJINmdGxiZ4Lve5Rp M3v4VFEzPjNzNkG5
WAD-1 NEjWWFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHTNVl2PTByIH7nM41t M{jaS|Q5KGh? M4LzOmROW09? NGm3ZYhKdmirYnn0d{Bk\WyuIHfyc5d1cA>? MkizNVI3OzF4MUm=
U266/LR7 NG\zTWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4SwO|UxOCCwZz;tcC=> NIf2T241QCCq MV;EUXNQ NYfZPXI6UW6qaXLpeJMh[2WubDDndo94fGh? NWLveYNNOTJ4M{G2NVk>
U266/dox4 MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPzenY2ODBibnevcYw> M2OzRlQ5KGh? NGHPWpVFVVOR NWLIZpRNUW6qaXLpeJMh[2WubDDndo94fGh? NGjHSXQyOjZ|MU[xPS=>
RPMI8226/LR5 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mof3OVAxKG6pL33s NH;ETm01QCCq NHHvdFFFVVOR NWH5dopGUW6qaXLpeJMh[2WubDDndo94fGh? MnzJNVI3OzF4MUm=
H460 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVixNEDPxE1? MVi3NkBp MljYSG1UVw>? Ml\5TWM2OD1zMECgcm0> NEO3O2syOjZ|MU[yNC=>
H358 NYjjdIlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnuxNVAh|ryP NIDFcG44OiCq MXvEUXNQ NHXqNI1KSzVyPUewJI5O M1\2TlEzPjNzNkKw
H322 NWnnV5F1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[xNEDPxE1? NH7YXmE4OiCq NYnHbWFjTE2VTx?= NWTsXmdoUUN3ME22NlAhdk1? MofpNVI3OzF4MkC=
H460 MVjGeY5kfGmxbjDBd5NigQ>? MVWxNFAhdk1? NEXPU2kzPCCq Mn:xSG1UVw>? MmSzTY5lfWOnczDHNk1ONXCqYYPlJIFzemW|dDDhcoQhfHWkdXzpckBie3OnbXLsfU1lcXOjc4PlcYJtgQ>? NEO0NYYyOjZ|MU[yNC=>
LNCap-Pro5 M4XiUGZ2dmO2aX;uJGF{e2G7 MWCxJO69VQ>? MoLLOEBp M1KxZmROW09? M4TxcXN1[WKrbHn6[ZMheDV| MXSxOFYyOjV|Mh?=
T29 NVXteIJWSXCxcITvd4l{KEG|c3H5 NX\PeZZnPTBibl2= MnTuOFghcCB? NH3a[pdFVVOR NF;INW5KdmS3Y3XzJINmdGxiYYDvdJRwe2m| M{HkZ|E3Pzd6MUe5
T29Kt1 Mn3jRZBweHSxc3nzJGF{e2G7 MXO1NEBvVQ>? NEHremY1QCCqIB?= MnL5SG1UVw>? NGX3bIRKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NXj5WIVDOTZ5N{ixO|k>
HCT116 M1;vWmFxd3C2b4Ppd{BCe3OjeR?= MljnOVAhdk1? MYW0PEBpKA>? NH\2eGpFVVOR MULJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MXOxOlc4QDF5OR?=
HKe-3 NYrMR2pNSXCxcITvd4l{KEG|c3H5 MkTrOVAhdk1? M3HlUFQ5KGhi NH3XfI1FVVOR MkG3TY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NV;aTmxZOTZ5N{ixO|k>
NB-1691 MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37KdFEh|ryP NIXPbo04OiCq NFOwfHBKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iNTW= MYqxO|Y5QTZ6NB?=
CHLA-255 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnGxNUDPxE1? NVvKSWczPzJiaB?= MVTJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOiV? NGTBSmoyPzZ6OU[4OC=>
SK-N-AS MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV2xJO69VQ>? Mn;sO|IhcA>? M{DhWWlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyBzMDW= NYDGN2s1OTd4OEm2PFQ>
NB-1691 MXLGeY5kfGmxbjDBd5NigQ>? MY[xNEBvVQ>? MXSyOEBp NWnoXGczW2mpbnnmbYNidnSueTDy[YR2[2W|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\Q>? MV:xO|Y5QTZ6NB?=
CHLA-255 M2nWSWZ2dmO2aX;uJGF{e2G7 NGnZWVkyOCCwTR?= NWLGWWJSOjRiaB?= M4TFNG1w\GW|dHz5JJJm\HWlZYOgZ4VtdHNiaX6geIhmKEdyL1exJJBp[XOn Mn7MNVc3QDl4OES=
RPMI 8226 MlrsSpVv[3Srb36gRZN{[Xl? NWjrV|BpOjBibl2= M3PuXVghcA>? MkWyV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> MnzPNVk1OzZyNUC=
MM.1S MorGSpVv[3Srb36gRZN{[Xl? NXvzXZJlOjBibl2= M3rNdlghcA>? M4HndnNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 NX;XVodOOTl2M{[wOVA>
U266 MnrjSpVv[3Srb36gRZN{[Xl? NX\PeXNrOjBibl2= NGLBe2I5KGh? NVHnTGU6W2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? M{HhelE6PDN4MEWw
OPM1 MonrSpVv[3Srb36gRZN{[Xl? NXHheXFnOjBibl2= NF\IZZk5KGh? NGXucI9UcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? MVexPVQ{PjB3MB?=
INA6 NVeyblZiTnWwY4Tpc44hSXO|YYm= MWCyNEBvVQ>? M{LYd|ghcA>? M1TjNnNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 MmDiNVk1OzZyNUC=
OPM2 NHP1PZBHfW6ldHnvckBCe3OjeR?= MYSyNEBvVQ>? MX:4JIg> M3;NZ3Nq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 NIDEb3MyQTR|NkC1NC=>
RPMI 8226 NWXtXohkTnWwY4Tpc44hSXO|YYm= M3e5XFIxKG6P MlzpPEBp NYrydo8yUW6mdXPld{BFVkFic4nueIhme2m| NVTRbIJSOTl2M{[wOVA>
BaF/3 NUO0SI41T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PyV|ExOCCwTR?= NIPkTpk1QCCq M3HhV2lEPTB;Nj6yJI5O MlzjNlA{ODV4OUK=
BaF/3-p210 MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnISWoyODBibl2= M{mzXVQ5KGh? NGLOdFhKSzVyPUSuO{BvVQ>? NFjreJYzODNyNU[5Ni=>
TCC-S NU\6V4hKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1u0VFExOCCwTR?= Mn7EOFghcA>? Mn\UTWM2OD1{Lkigcm0> NH;BRpgzODNyNU[5Ni=>
BaF/3 NYntc|lPTnWwY4Tpc44hSXO|YYm= MoTUOkBvVQ>? MnvPOFghcA>? NEnFc3dKdmS3Y3XzJIEh\3KnYYSgS|Eh[2WubD3jfYNt\SCjcoLld5Q> M3;nPFIxOzB3Nkmy
BaF/3-p210 NGnmSW9HfW6ldHnvckBCe3OjeR?= MlfOOkBvVQ>? MnXpOFghcA>? MoPzTY5lfWOnczDhJJNtcWeqdDDHNUBk\WyuLXP5Z4xmKGG{cnXzeC=> NXSxd49JOjB|MEW2PVI>
BaF/3-p210 NH65PWpHfW6ldHnvckBCe3OjeR?= NXfiSJR1PiCwTR?= Mn[0NlQhcA>? M4TPVnJm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBidmRidHjlJIFkfGm4aYT5JI9nKFKk NX3z[IRUOjB|MEW2PVI>
Raji MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jv[lEh|ryP NFfzUZYzPCCq NX;NbpNrWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg M2XEXVIyOTdyOUi4
LCL-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nQXlEh|ryP Mo\SNlQhcA>? MXTS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MmTRNlEyPzB7OEi=
LCL-2 M4S1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXuxJO69VQ>? NVu0OVl3OjRiaB?= MmnsVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi M4rS[|IyOTdyOUi4
BJAB MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3UN5AyKM7:TR?= Mle4NlQhcA>? NUOz[mx{WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg M3vEcVIyOTdyOUi4
SNT-13 Mo\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYixJO69VQ>? M{fwXlI1KGh? M1;zeHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MlzjNlEyPzB7OEi=
SNT-16 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWP4e4pvOSEQvF2= NX;NXWg3OjRiaB?= NGT2fWhT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MVGyNVE4ODl6OB?=
Jurkat MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIm0eVMyKM7:TR?= Ml[0NlQhcA>? NWrjXm13WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NVm2[pVGOjFzN{C5PFg>
KAI-3 NFjRcnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzsTYN3OSEQvF2= M3TZWFI1KGh? M4Xqc3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NXjsSXZMOjFzN{C5PFg>
SNK-6 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3lRVUyKM7:TR?= MoHYNlQhcA>? M{nXcnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= M3nwTlIyOTdyOUi4
KHYG-1 MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjSNUDPxE1? MojENlQhcA>? MXrS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NXK5WGJlOjFzN{C5PFg>
SNT-16 MWLBdI9xfG:|aYOgRZN{[Xl? MlXyNUDPxE1? MkWzOkBp NFnkSpRKdmS3Y3XzJINmdGxiYYDvdJRwe2m| M33qRVIyOTdyOUi4
Jurkat NFzFZ49CeG:ydH;zbZMhSXO|YYm= NELEcYsyKM7:TR?= MnTnOkBp NHvKTGVKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MoCzNlEyPzB7OEi=
KAI-3 NVf4[lZYSXCxcITvd4l{KEG|c3H5 M373eFEh|ryP M1vh[VYhcA>? MYPJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NFHrd5czOTF5MEm4PC=>
KHYG-1 MmqyRZBweHSxc3nzJGF{e2G7 M3XYU|Eh|ryP NYGwNIkxPiCq M13ROmlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MV6yNVE4ODl6OB?=
SNT-13 NHHQbnRCdnSrdnnyZYwhSXO|YYm= NV3kSpNGOSEQvF2= NXPsbYduOjRiaB?= NH\CfY1KdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? MX:yNVE4ODl6OB?=
SNT-16 M4XacmFvfGm4aYLhcEBCe3OjeR?= NX[5RotqOSEQvF2= MorvNlQhcA>? MnnHTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX M2mzUlIyOTdyOUi4
KAI-3 MkjyRY51cX[rcnHsJGF{e2G7 NYjoXlJGOSEQvF2= NXnhXG9LOjRiaB?= MYTJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> NFzob5YzOTF5MEm4PC=>
SNK-6 NW\2ZmVkSW62aY\pdoFtKEG|c3H5 MkPMNUDPxE1? MmfCNlQhcA>? NVKwVmhxUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY MoTvNlEyPzB7OEi=
RAW 264.7 M{GzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWexNFAhdk1? NV;Cb3lpPDhiaB?= M4LtZ3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NFzsd3UzOjR{N{G1OC=>
A375 MUjBdI9xfG:|aYOgRZN{[Xl? MWixNEBvVQ>? NXHSeIFvOjRiaB?= MlPZTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MXGyN|A4QTB6Mx?=
BLM MmHqRZBweHSxc3nzJGF{e2G7 Mn:5NVAhdk1? NGTlV4YzPCCq MYrJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MV2yN|A4QTB6Mx?=
A375 NGfSNlNCfXSxcHjh[5khSXO|YYm= NXTpTlB4OTBibl2= MkD6NVIhcA>? MVjJcoR2[2W|IH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= MmHaNlMxPzlyOEO=
BLM MWLBeZRweGijZ4mgRZN{[Xl? M37PfFExKG6P M1nQN|EzKGh? MU\JcoR2[2W|IH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= NH;6TGgzOzB5OUC4Ny=>
H1299 NEXiW4hCeG:ydH;zbZMhSXO|YYm= M2ftPVgxKG6P MnnTNlQhcA>? Mn;uSG1UVw>? Mnn2V4Vve2m2aYrld{BPW0OOQzDj[YxteyC2bzDNV2Mu\GW{aY\l[EBqSzlvaX7keYNm\CCjcH;weI9{cXN? NEDpdI0zPTN{M{[5Ny=>
Hut-78 MnnNSpVv[3Srb36gRZN{[Xl? MYixNFAhdk1? MmHRNlQhcA>? Mnq0SG1UVw>? M1;3fGRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTBiZYjwdoV{e2mxbh?= MUGyOVY5OTN|NR?=
H9 NUPwOIEyTnWwY4Tpc44hSXO|YYm= NIHLc5QyODBibl2= Mme2NlQhcA>? NWK4bVltTE2VTx?= MWDEc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVEyKGW6cILld5Nqd25? MVOyOVY5OTN|NR?=
HH M{TKVGZ2dmO2aX;uJGF{e2G7 Mme4NVAxKG6P Ml3UNlQhcA>? NFzMdoFFVVOR NUe1WXR{\G:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMjDlfJBz\XO|aX;u NV7tZ2NZOjV4OEGzN|U>
Hut-78 M1\ZZW1q\3KjdHnvckBCe3OjeR?= M4nGRVExOCCwTR?= Mn\JNlQhcA>? NHfGRYpFVVOR NImwXHNT\WS3Y3XzJINmdGxibXnndoF1cW:wIHL5JFgx6oDVOUCl M1rDT|I2PjhzM{O1
HH M33PWW1q\3KjdHnvckBCe3OjeR?= M4TnO|ExOCCwTR?= NI\0OJIzPCCq M1ThRWROW09? NXfuUI83WmWmdXPld{Bk\WyuIH3p[5JifGmxbjDifUA5OOLCk{mxKS=> MkfGNlU3QDF|M{W=
U937 NEm2V4VHfW6ldHnvckBCe3OjeR?= MX6xNFAhdk1? NY\BTG9mPiCq M2qxO2lv\HWlZYOgTWwuQCCneIDy[ZN{cW:wIHnuJGxRWy2|dHnteYxifGWmIGW5N|chdWGlcn;wbIFo\XN? MV2yOVc6OTR5Nx?=
human PBMC Mn;3SpVv[3Srb36gRZN{[Xl? MY[xNFAhdk1? NXvhcJpVOjRiaB?= M1jNfmlv\HWlZYOgTWwuQCC{ZXzlZZNm NVv0NlJiOjV5OUG0O|c>
ES6 MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3S0N2lEPTB;MD6wNFIyKG6P NHTuU4pUSU6JRWK=
SK-UT-1 NF;oNotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nOU2lEPTB;MD6xOlMhdk1? MX7TRW5ITVJ?
SH-4 M3[yPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH65R21KSzVyPUCuNVc{KG6P M4C5ZnNCVkeHUh?=
TE-9 M1vuSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTDVXZKSzVyPUCuNVgzKG6P NF\yVmhUSU6JRWK=
A253 NHPqfFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Tic2lEPTB;MD6yNFghdk1? NYP1WJBCW0GQR1XS
no-10 NVradnI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jOdGlEPTB;MD6yNUBvVQ>? NVjJO2ZyW0GQR1XS
MMAC-SF NFr2eFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwMkG2JI5O MYTTRW5ITVJ?
A101D NFK2UGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUP3S2tCUUN3ME2wMlIzPSCwTR?= MVfTRW5ITVJ?
NTERA-S-cl-D1 NEn4RmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfvTWM2OD1yLkK0N{BvVQ>? NE\kbmxUSU6JRWK=
8-MG-BA NHTGOW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3ZTWM2OD1yLkK1JI5O MnfjV2FPT0WU
KNS-42 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M174[GlEPTB;MD6yOVghdk1? NVzTS25NW0GQR1XS
LXF-289 NIHwe|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwMk[5JI5O M2DIfXNCVkeHUh?=
OVCAR-4 NF2wV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjNTWM2OD1yLkK4PUBvVQ>? MoK2V2FPT0WU
LOUCY MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwMkmzJI5O M{D6cnNCVkeHUh?=
BB65-RCC MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF6yXYtKSzVyPUCuN|A1KG6P MonvV2FPT0WU
D-542MG M3TVPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDHdnlKSzVyPUCuN|I6KG6P MV3TRW5ITVJ?
ONS-76 M{C4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk[wTWM2OD1yLkOzJI5O M3GxXnNCVkeHUh?=
BB30-HNC NWDvVVVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHjOI5iUUN3ME2wMlM{PSCwTR?= NGXnd|dUSU6JRWK=
KS-1 NWjmWWhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDlTWM2OD1yLkO0JI5O MYfTRW5ITVJ?
A388 NGDKUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37wZmlEPTB;MD6zOVYhdk1? NFnFTHlUSU6JRWK=
ES8 M{Czd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwNDDuUS=> MonhV2FPT0WU
MZ2-MEL NV7DOFNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfFTWM2OD1yLkSwO{BvVQ>? MYHTRW5ITVJ?
HCC2998 MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXS1bYR2UUN3ME2wMlQyOiCwTR?= MnPwV2FPT0WU
D-247MG NITXXWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\UcI5KSzVyPUCuOFE{KG6P NH\S[phUSU6JRWK=
ACN MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXCeIJOUUN3ME2wMlQyPyCwTR?= NYX4ZmtqW0GQR1XS
LB2518-MEL NHzEeWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;nfWlEPTB;MD60NlUhdk1? MWXTRW5ITVJ?
ES1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jOSWlEPTB;MD60N{BvVQ>? MmjUV2FPT0WU
HCE-T MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwNEO5JI5O NEX5dVlUSU6JRWK=
OS-RC-2 NHHoNG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFz3U2RKSzVyPUCuOFQhdk1? MYTTRW5ITVJ?
MFH-ino MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwNESzJI5O MkLuV2FPT0WU
OCUB-M NFjTbndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv4cHlzUUN3ME2wMlQ1PyCwTR?= M2\MdXNCVkeHUh?=
CP66-MEL Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnpTWM2OD1yLkS3N{BvVQ>? MXPTRW5ITVJ?
LB771-HNC NE\6XYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nITmlEPTB;MD60O|Qhdk1? MVLTRW5ITVJ?
DSH1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwNEigcm0> NF;2T2tUSU6JRWK=
HUTU-80 M4TsfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37wfGlEPTB;MD61N|Mhdk1? Mn6wV2FPT0WU
CESS NYPRcWNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC5[pI2UUN3ME2wMlU{QCCwTR?= M33BOHNCVkeHUh?=
NCI-H747 NEH6[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\UTWM2OD1yLkWzPUBvVQ>? NVrtUJM5W0GQR1XS
HT-144 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHGNldTUUN3ME2wMlU4PiCwTR?= MlL4V2FPT0WU
COLO-829 M2DOe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mln2TWM2OD1yLk[xOEBvVQ>? MnzEV2FPT0WU
A4-Fuk NWfi[4xZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHwTWM2OD1yLk[yN{BvVQ>? NGnVSoNUSU6JRWK=
GI-ME-N NXPSS5VmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\5VXhKSzVyPUCuOlM1KG6P NHHrOVRUSU6JRWK=
LB831-BLC MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwNkSxJI5O M2fjWXNCVkeHUh?=
HOP-62 M1vzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\sRmlEPTB;MD62OFchdk1? M4H6VnNCVkeHUh?=
BB49-HNC NGS0eWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\5TWM2OD1yLk[1NkBvVQ>? MYLTRW5ITVJ?
D-336MG NHjjW3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULLV|VJUUN3ME2wMlY2PyCwTR?= NYfBVHRHW0GQR1XS
TK10 MnHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkj1TWM2OD1yLk[3PUBvVQ>? NFTPW3VUSU6JRWK=
Ramos-2G6-4C10 NWr1fXBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTDeXZpUUN3ME2wMlY6OyCwTR?= NV3YZ|FoW0GQR1XS
LB373-MEL-D NVvpVG1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;jWWlEPTB;MD63JI5O NFXQTJdUSU6JRWK=
SF126 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwN{CxJI5O M3mxW3NCVkeHUh?=
UACC-257 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwN{Ggcm0> M1zBNXNCVkeHUh?=
KINGS-1 NHnVNW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVKyWmcyUUN3ME2wMlczOiCwTR?= NFzmcXVUSU6JRWK=
LS-513 NYPIRpJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{j6eWlEPTB;MD63N|khdk1? M4XDeHNCVkeHUh?=
GI-1 NUW3S3dUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUm5TXhoUUN3ME2wMlc3PCCwTR?= NFrPeYtUSU6JRWK=
ES7 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEe1PHdKSzVyPUCuO|Y3KG6P NIHGblJUSU6JRWK=
LB2241-RCC NWLnVXZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHWTWM2OD1yLkiwOEBvVQ>? MYnTRW5ITVJ?
D-263MG MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\BcGlEPTB;MD64NFchdk1? MXTTRW5ITVJ?
SW684 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWD6N|F4UUN3ME2wMlgzOSCwTR?= MVPTRW5ITVJ?
ML-2 M3LlN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;kNVlxUUN3ME2wMlgzOSCwTR?= NYTGTYdpW0GQR1XS
SK-LMS-1 NWjrc453T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnT4TWM2OD1yLki1OEBvVQ>? MVzTRW5ITVJ?
TE-5 M3K2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\tSGlEPTB;MD64OlUhdk1? NWDRbYdKW0GQR1XS
QIMR-WIL NXXyRm42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\Xc3FKSzVyPUCuPFg6KG6P NH;LbVVUSU6JRWK=
NCI-H1355 M2LBWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDKdJBtUUN3ME2wMlg6PSCwTR?= M2XwenNCVkeHUh?=
SNB75 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVX4cIZiUUN3ME2wMlkyOiCwTR?= MWDTRW5ITVJ?
RXF393 NF3YTVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjPboVkUUN3ME2wMlkyPCCwTR?= MXPTRW5ITVJ?
IST-MEL1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HJRWlEPTB;MD65NVchdk1? NWLCNI8{W0GQR1XS
SF268 M4nmdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYm1SXNSUUN3ME2wMlkzOyCwTR?= MV;TRW5ITVJ?
KALS-1 M3jOSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\XfG5SUUN3ME2wMlkzPSCwTR?= M4PSc3NCVkeHUh?=
HC-1 MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEe1WWVKSzVyPUCuPVc2KG6P MYTTRW5ITVJ?
SW872 MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTBwOUm2JI5O NES0XHpUSU6JRWK=
PSN1 M4D6Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTFwMEGgcm0> MoP2V2FPT0WU
TE-1 NX3XV2FRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rySGlEPTB;MT6wN{BvVQ>? NXHEUZpsW0GQR1XS
TE-10 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\iRWlKSzVyPUGuNFMhdk1? MYHTRW5ITVJ?
RKO NIKyfZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfSeG9KSzVyPUGuNFYhdk1? MUTTRW5ITVJ?
LC-2-ad MojNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF2z[2hKSzVyPUGuNFghdk1? NXr5Rm5UW0GQR1XS
SK-MM-2 NXj1UFk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTFwMEmgcm0> M3;OPHNCVkeHUh?=
VA-ES-BJ NWTjVYRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PUcGlEPTB;MT6wPUBvVQ>? MoPCV2FPT0WU
MZ7-mel M2i2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTzTI1KSzVyPUGuNFkhdk1? NE\weXZUSU6JRWK=
D-392MG M4DQcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXXTWM2OD1zLkGgcm0> NEe5cIdUSU6JRWK=
CCRF-CEM MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTFwMUOgcm0> Mn7NV2FPT0WU
EM-2 Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTFwMU[gcm0> MVXTRW5ITVJ?
HAL-01 NX;n[|hPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTye5ZKUUN3ME2xMlE5KG6P M1XlcXNCVkeHUh?=
TE-8 NVX2WFl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3HeGJKSzVyPUGuNVkhdk1? NHj2NphUSU6JRWK=
NCI-H1882 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\SSoxyUUN3ME2xMlIhdk1? NWr6ZpJIW0GQR1XS
Daudi MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnIcZhKSzVyPUGuNlIhdk1? NHnwd5RUSU6JRWK=
BL-41 NVvibIxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHj2fWlKSzVyPUGuNlUhdk1? MoXhV2FPT0WU
SR NID0[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTFwMkWgcm0> MVjTRW5ITVJ?
KM12 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFu4WnVKSzVyPUGuNlchdk1? NUHUUI52W0GQR1XS
K5 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTFwMkigcm0> NG\wbWxUSU6JRWK=
A3-KAW Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnQ[XdKSzVyPUGuNlghdk1? NILnXWJUSU6JRWK=
CMK MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFwMkmgcm0> NUCxfWptW0GQR1XS
Calu-6 M2\1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHXR4xKSzVyPUGuNlkhdk1? NWHPcoJjW0GQR1XS
IST-SL2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TFZmlEPTB;MT6zNUBvVQ>? MWPTRW5ITVJ?
OPM-2 M4KwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDGTWM2OD1zLkOzJI5O M{LZb3NCVkeHUh?=
DU-4475 NYflOGdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTQTWM2OD1zLkO2JI5O M1G4dXNCVkeHUh?=
ECC12 Mn7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\ySlhKSzVyPUGuN|chdk1? MYLTRW5ITVJ?
L-540 MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PqZ2lEPTB;MT6zO{BvVQ>? MnL3V2FPT0WU
CAS-1 NUnTSHFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknDTWM2OD1zLkO3JI5O MlL3V2FPT0WU
PF-382 NXPrRVgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LTZmlEPTB;MT60O{BvVQ>? NIL0N|FUSU6JRWK=
LS-411N M3;aOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX75WGZDUUN3ME2xMlU{KG6P MoHsV2FPT0WU
NCI-H69 M1vXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3KOIpKSzVyPUGuOVQhdk1? Mn7OV2FPT0WU
NB12 M2HJbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHziWVhKSzVyPUGuOVYhdk1? MofkV2FPT0WU
HEL M3vVemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jxSGlEPTB;MT62NUBvVQ>? MWDTRW5ITVJ?
GCIY MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHSVIZKSzVyPUGuOlIhdk1? MYDTRW5ITVJ?
EHEB NEDNWWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml30TWM2OD1zLk[3JI5O MUPTRW5ITVJ?
TGBC1TKB M4PMc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWSyb4N[UUN3ME2xMlcyKG6P NVzUOGFWW0GQR1XS
KURAMOCHI NIW2V4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PrbGlEPTB;MT63NkBvVQ>? MlfjV2FPT0WU
U-266 M2SxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PoWGlEPTB;MT63OkBvVQ>? NHjGUHRUSU6JRWK=
LC4-1 NITT[|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPxTWM2OD1zLke5JI5O NUXmboNXW0GQR1XS
NCI-H2126 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXQWJdKSzVyPUGuPEBvVQ>? MV7TRW5ITVJ?
NCI-H1092 NEi4PVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTFwODDuUS=> NH\q[pJUSU6JRWK=
GB-1 NVribWxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTFwOEGgcm0> MX;TRW5ITVJ?
MV-4-11 MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;HTWM2OD1zLkiyJI5O NH6xWWZUSU6JRWK=
Becker NUXY[JlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTFwOEOgcm0> Mnq2V2FPT0WU
MPP-89 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\0Z2lEPTB;MT64PUBvVQ>? MlzUV2FPT0WU
BE-13 NIfNUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{CyUmlEPTB;MT65N{BvVQ>? NGLTS4NUSU6JRWK=
697 NEG1S|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTFwOUmgcm0> MVvTRW5ITVJ?
NKM-1 MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTJibl2= MYDTRW5ITVJ?
NB13 NFL3WFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYm0d|RVUUN3ME2yJI5O MXfTRW5ITVJ?
LS-123 MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLySo1KSzVyPUKuNFIhdk1? MmHYV2FPT0WU
NB17 MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrPbnZKSzVyPUKuNFQhdk1? NGPoVGxUSU6JRWK=
LAN-6 M1nLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLpc|JoUUN3ME2yMlA2KG6P NVPPV3RFW0GQR1XS
EW-24 MmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnhXllKUUN3ME2yMlA5KG6P M3HTe3NCVkeHUh?=
NOS-1 M4iwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4m2PWlEPTB;Mj6xNUBvVQ>? MYnTRW5ITVJ?
BL-70 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWntdG9PUUN3ME2yMlEzKG6P NEXHRWtUSU6JRWK=
GT3TKB M3vJSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPwepAxUUN3ME2yMlEzKG6P NGDCNVBUSU6JRWK=
HH NHXiSplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPWTWM2OD1{LkGzJI5O MnK0V2FPT0WU
KE-37 Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTJwMUOgcm0> NH7EOmdUSU6JRWK=
MOLT-4 NFfJRoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[0TWM2OD1{LkGzJI5O NXTXS2ozW0GQR1XS
EKVX NGfBXGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTJwMUSgcm0> MnLyV2FPT0WU
KGN MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;nbYE{UUN3ME2yMlE2KG6P MXHTRW5ITVJ?
ES4 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nSRWlEPTB;Mj6xOkBvVQ>? M13nXnNCVkeHUh?=
SJSA-1 M1r4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;MTWM2OD1{LkKxJI5O MlPTV2FPT0WU
KMOE-2 M3:ybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTJwMkOgcm0> NE\we21USU6JRWK=
NB5 M4jaTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzLTWM2OD1{LkK3JI5O NEHzR2hUSU6JRWK=
BC-1 MmHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3icmFDUUN3ME2yMlMyKG6P NWjJWppyW0GQR1XS
NB10 NGrDU2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX32eXllUUN3ME2yMlMzKG6P M{jwN3NCVkeHUh?=
RPMI-8226 NGLXUXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJwM{Wgcm0> MmToV2FPT0WU
SCC-3 NVnjO5FZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFe2OY5KSzVyPUKuN|chdk1? M{jne3NCVkeHUh?=
ARH-77 MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vYdWlEPTB;Mj6zPEBvVQ>? NWnueWlbW0GQR1XS
NCI-H748 NVfUSI5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37BXGlEPTB;Mj6zPUBvVQ>? NHPFO2tUSU6JRWK=
KU812 NHvFUGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[3O4RKSzVyPUKuOFIhdk1? NVPVe3lUW0GQR1XS
NCI-H64 NGDOUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojUTWM2OD1{LkS0JI5O NVG4NHhpW0GQR1XS
NB69 M3GyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEOyfIVKSzVyPUKuOFYhdk1? NITrcHFUSU6JRWK=
KNS-81-FD MmK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvQfZMzUUN3ME2yMlQ5KG6P Ml3hV2FPT0WU
LB1047-RCC M1XPZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJwNUegcm0> NEnLXVRUSU6JRWK=
EB-3 M{K5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;jTWM2OD1{Lk[2JI5O MWDTRW5ITVJ?
Mo-T MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLjUWdKSzVyPUKuO|Qhdk1? NGK5XmlUSU6JRWK=
EW-16 NVv0W2tlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nBO2lEPTB;Mj63OUBvVQ>? MmfYV2FPT0WU
CTV-1 MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTJwODDuUS=> MX7TRW5ITVJ?
ETK-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTJwOESgcm0> NF;jO2FUSU6JRWK=
C2BBe1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJwOEmgcm0> Mo\5V2FPT0WU
MOLT-16 NFnHVJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLmTWM2OD1{Lki5JI5O MoXFV2FPT0WU
SW954 MkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;3VGlEPTB;Mj65JI5O NEjn[Y9USU6JRWK=
HT NXHqeJRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVP6[XdKUUN3ME2zMlAzKG6P NVu3WnRUW0GQR1XS
KARPAS-299 NUjHR2h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTNwME[gcm0> MofmV2FPT0WU
MONO-MAC-6 M{TyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjZ[m4xUUN3ME2zMlEhdk1? NYOzVJhEW0GQR1XS
CGTH-W-1 Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTNwMTDuUS=> NWnBN2N1W0GQR1XS
SK-PN-DW NHfj[HFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jRTGlEPTB;Mz6xOEBvVQ>? NG\tc3hUSU6JRWK=
CW-2 NXzQeFh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nGT2lEPTB;Mz6yNUBvVQ>? M1njc3NCVkeHUh?=
SK-N-DZ MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3RTWM2OD1|LkK2JI5O M4fZVXNCVkeHUh?=
NEC8 M1vRZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfPc28xUUN3ME2zMlM2KG6P NUPpeVVQW0GQR1XS
LB996-RCC MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjKTWM2OD1|LkSgcm0> MlrXV2FPT0WU
DB MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTNwNEGgcm0> MljyV2FPT0WU
TE-15 M4Pq[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HPSWlEPTB;Mz60N{BvVQ>? NXv3WHgxW0GQR1XS
COR-L88 M4D2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLWTWM2OD1|LkS3JI5O Ml;2V2FPT0WU
LAMA-84 NVPaW3hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTNwNEmgcm0> MkXUV2FPT0WU
MEG-01 M1fHUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjUVpgxUUN3ME2zMlQ6KG6P MVzTRW5ITVJ?
LOXIMVI NY[wZ2U5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\2T2lEPTB;Mz61JI5O MYPTRW5ITVJ?
RPMI-8402 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPNTlVKSzVyPUOuOUBvVQ>? NWC3PHVzW0GQR1XS
KARPAS-45 MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXIeXpyUUN3ME2zMlU1KG6P NG\NNW5USU6JRWK=
HCC1187 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTNwNUSgcm0> Mm\HV2FPT0WU
MZ1-PC M4e4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTNwNUSgcm0> NUDvN2NpW0GQR1XS
no-11 NHqw[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mme3TWM2OD1|LkW1JI5O MUXTRW5ITVJ?
EVSA-T Mnj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFP1eVRKSzVyPUOuOkBvVQ>? MVvTRW5ITVJ?
DJM-1 NH7pXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFezS2FKSzVyPUOuOlMhdk1? MmPiV2FPT0WU
COLO-684 M4XaTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoizTWM2OD1|Lk[2JI5O NF;lPZNUSU6JRWK=
NMC-G1 NYPF[IQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnj6TWM2OD1|Lk[4JI5O NYXLVYtSW0GQR1XS
LC-1F NXPYbpBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEmxOYRKSzVyPUOuO|Qhdk1? NEfuS|lUSU6JRWK=
RL95-2 M3vxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfQZ4tRUUN3ME2zMlc6KG6P MlK0V2FPT0WU
COLO-320-HSR NGXGbodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjkXmx7UUN3ME2zMlkzKG6P MUjTRW5ITVJ?
RCC10RGB M12wUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYW3SpNmUUN3ME2zMlk{KG6P NV3RbWV7W0GQR1XS
HD-MY-Z M4fFO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjtNpI{UUN3ME2zMlk{KG6P MmDYV2FPT0WU
NCI-H2141 M4PJeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3OyVGlEPTB;ND6wOUBvVQ>? M1y0dXNCVkeHUh?=
K-562 M33rTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17jWWlEPTB;ND6xNkBvVQ>? NXXlS2VkW0GQR1XS
NCI-H1648 NVLK[G91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXGTWM2OD12LkGzJI5O MYTTRW5ITVJ?
OMC-1 NHHldHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnTNHRDUUN3ME20MlE5KG6P MmDqV2FPT0WU
LB647-SCLC NHLDPYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID1dJRKSzVyPUSuNlIhdk1? MY\TRW5ITVJ?
TE-12 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUm3PZdrUUN3ME20MlI2KG6P M{e4d3NCVkeHUh?=
NOMO-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzrTWM2OD12LkOzJI5O MVfTRW5ITVJ?
Raji MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXxb4ZqUUN3ME20MlQ3KG6P NVL6ZXJLW0GQR1XS
NALM-6 M2LESGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfGcFJKSzVyPUSuOFkhdk1? MlfWV2FPT0WU
HL-60 MoLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3e3XGlEPTB;ND62O{BvVQ>? MYTTRW5ITVJ?
IST-SL1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlKxTWM2OD12Lk[4JI5O NVnudIltW0GQR1XS
MHH-PREB-1 Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4OzU2lEPTB;ND64OkBvVQ>? MWPTRW5ITVJ?
MHH-NB-11 NYjE[o1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPRdVlGUUN3ME20MlkyKG6P MnPmV2FPT0WU
JiyoyeP-2003 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDz[4pIUUN3ME21JI5O NXLabYFvW0GQR1XS
SBC-1 NXvlSItUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHnZZJmUUN3ME21MlAyKG6P M4jDVnNCVkeHUh?=
CHP-126 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfUPIJLUUN3ME21MlA3KG6P MYrTRW5ITVJ?
LU-139 NYe4SWZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGL4PW9KSzVyPUWuNVMhdk1? MXHTRW5ITVJ?
NCI-SNU-5 NIjlPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGO3VWVKSzVyPUWuNVchdk1? MUnTRW5ITVJ?
SW962 M2XLbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELEfnNKSzVyPUWuNlEhdk1? NUHCNlJDW0GQR1XS
EW-1 Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHRTWM2OD13LkOxJI5O NXPNfHc3W0GQR1XS
NCI-H1417 M3X2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[0b2lEPTB;NT61NUBvVQ>? Ml74V2FPT0WU
LU-65 MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIm5dHFKSzVyPUWuPFQhdk1? NXi3dlVuW0GQR1XS
D-502MG MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HwcGlEPTB;Nj6zO{BvVQ>? NVHH[JVMW0GQR1XS
BC-3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTZwNkGgcm0> Mn3sV2FPT0WU
GDM-1 M1K0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\4e4ZKSzVyPU[uO|chdk1? MWfTRW5ITVJ?
NCI-H2196 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\sO2JKSzVyPU[uPEBvVQ>? MoXrV2FPT0WU
NB1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zyeWlEPTB;Nj64PEBvVQ>? NXfpSFZKW0GQR1XS
NCI-H345 M1;RWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\wW5hRUUN3ME23MlIhdk1? NULvV|VbW0GQR1XS
SU-DHL-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjYRVdZUUN3ME23MlI1KG6P MnPGV2FPT0WU
JVM-2 MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zGfWlEPTB;Nz6yPEBvVQ>? MYHTRW5ITVJ?
LU-134-A NUnVdFNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{O3e2lEPTB;Nz6zPUBvVQ>? NVfGS3d5W0GQR1XS
NCI-H1694 NY\sZlJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlH2TWM2OD15LkW4JI5O M4nZVnNCVkeHUh?=
NCI-SNU-16 MnrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[wcY5UUUN3ME23MlY2KG6P MV;TRW5ITVJ?
L-363 M2fLbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPxTWM2OD15Lkegcm0> M4[wPHNCVkeHUh?=
KG-1 MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFmxWJRKSzVyPUeuPVQhdk1? MWnTRW5ITVJ?
MN-60 NFrvVYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXBRo5JUUN3ME24MlE1KG6P MXfTRW5ITVJ?
NB6 M3njdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRThwNEigcm0> M1XZc3NCVkeHUh?=
MLMA MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHoZ5I4UUN3ME24Mlg2KG6P MlzMV2FPT0WU
ATN-1 NUDlcHdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XUUmlEPTB;OD64PUBvVQ>? NHnDTWNUSU6JRWK=
SK-NEP-1 NGXHdWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrqUHQ{UUN3ME25MlAyKG6P MXnTRW5ITVJ?
DMS-114 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkflTWM2OD17Lk[yJI5O M2Lh[HNCVkeHUh?=
CTB-1 M2XBPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTlwNkegcm0> NYPtZldvW0GQR1XS
NCI-H2081 MnLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHDfndKSzVyPUGwMlA6KG6P NWDlbIZSW0GQR1XS
ES5 MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfyTWM2OD1zMD6zPEBvVQ>? M2fTOXNCVkeHUh?=
HCC1599 MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvOOZhKSzVyPUGxMlkyKG6P Mof3V2FPT0WU
NCI-H23 M4LETWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofXTWM2OD1zMj6xNkBvVQ>? NITIdGVUSU6JRWK=
NCI-H1581 M4fiSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTF{LkK4JI5O M2nad3NCVkeHUh?=
JVM-3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vzSmlEPTB;MUKuPVkhdk1? MkH2V2FPT0WU
NCI-SNU-1 NHfjOpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfWTWM2OD1zMz6xPUBvVQ>? NHjOSm5USU6JRWK=
NB7 NHTWTWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHzTWM2OD1zNT65NkBvVQ>? MkTGV2FPT0WU
JAR NXi1epA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPYTmNKSzVyPUG2MlE{KG6P MVHTRW5ITVJ?
TGW M1W0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP5[WZ5UUN3ME2xOk41QCCwTR?= MlKyV2FPT0WU
U-87-MG M4PWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTF4Lke2JI5O NHu5cJhUSU6JRWK=
NCI-H1436 MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTF5LkCxJI5O M1nSW3NCVkeHUh?=
GOTO M2DXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\qWGlEPTB;MUeuNFYhdk1? NU\BU5BrW0GQR1XS
COLO-800 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPiVXNKSzVyPUG3MlY1KG6P NHjhVGhUSU6JRWK=
MFM-223 MkLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofITWM2OD1zNz65NUBvVQ>? M1znTnNCVkeHUh?=
EW-18 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjPTWM2OD1zNz65OkBvVQ>? NXXIbpdYW0GQR1XS
NB14 NUfrUpRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\XUGlEPTB;MUeuPVghdk1? NHfTZXlUSU6JRWK=
EB2 MmezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEG2Tm9KSzVyPUG4MlA5KG6P NXnrZXlMW0GQR1XS
EoL-1- NHfVZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:x[Ic2UUN3ME2xPE4{OSCwTR?= MWPTRW5ITVJ?
NCCIT MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLLTWM2OD1zOD6zOkBvVQ>? M2r5V3NCVkeHUh?=
DG-75 M4i0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\FV2RKSzVyPUG4MlYyKG6P M1TocnNCVkeHUh?=
HCC2218 NFjFc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ywTWlEPTB;MUmuOUBvVQ>? NWLWUlJXW0GQR1XS
TE-6 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfNTWM2OD1{MD6wPEBvVQ>? MUfTRW5ITVJ?
SF539 NUnJXohHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUn4OZRwUUN3ME2yNE43PyCwTR?= MVPTRW5ITVJ?
NCI-H446 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\DT|BKSzVyPUKxMlE5KG6P NWTm[WZWW0GQR1XS
IST-MES1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnewTWM2OD1{Mj63O{BvVQ>? M2P0cHNCVkeHUh?=
NCI-H82 M1rzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;NSpJKSzVyPUKzMlAzKG6P NFWzT4FUSU6JRWK=
HCC2157 M2T6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[wcWlEPTB;MkOuNVMhdk1? M{Lsb3NCVkeHUh?=
EW-12 M3mxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\QUGlEPTB;MkOuNVchdk1? M2f0N3NCVkeHUh?=
SIMA MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjMWXgyUUN3ME2yN{4{QCCwTR?= NHjEOHpUSU6JRWK=
DOHH-2 NWm0RpdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTJ|LkS1JI5O MV7TRW5ITVJ?
IM-9 NEXkbYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3LfYJKSzVyPUKzMlU1KG6P MUTTRW5ITVJ?
EC-GI-10 NWHxW4dOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJ2LkKzJI5O NH;sZnZUSU6JRWK=
HDLM-2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTJ2LkW0JI5O M3;3OXNCVkeHUh?=
LS-1034 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[wU2lEPTB;MkWuO|Uhdk1? MXHTRW5ITVJ?
REH MmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTBd41KSzVyPUK2MlQyKG6P M2\6SXNCVkeHUh?=
LU-165 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rO[2lEPTB;Mk[uO|Ihdk1? MYPTRW5ITVJ?
NH-12 M{naT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXwS5Z4UUN3ME2yO{43PyCwTR?= MVfTRW5ITVJ?
WSU-NHL NHOzVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTJ6LkO5JI5O NYPw[ldLW0GQR1XS
ECC4 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2D1bWlEPTB;MkiuO|khdk1? NGHoZo9USU6JRWK=
OCI-AML2 NXPEUohbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJ7Lk[5JI5O NUHJPGNPW0GQR1XS
EW-3 NVvFcpVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjI[YtKSzVyPUOwMlU6KG6P NGjnNHdUSU6JRWK=
NCI-H526 M{\FfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXftc3d[UUN3ME2zNk42PCCwTR?= MofJV2FPT0WU
NCI-H719 NI\ETYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXL0[WZ2UUN3ME2zOE4{OSCwTR?= MXjTRW5ITVJ?
KARPAS-422 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYK5RpFGUUN3ME2zOU4xPCCwTR?= MmHkV2FPT0WU
SK-MEL-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrtSFRyUUN3ME2zOU4yPyCwTR?= Ml3MV2FPT0WU
ES3 M3T4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTN3LkG5JI5O NV3MNJZ{W0GQR1XS
UACC-812 NUe0T4pmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37pSmlEPTB;M{WuOFQhdk1? NF7iVIpUSU6JRWK=
C8166 M2i2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4m5dGlEPTB;M{WuO{BvVQ>? NHfoemNUSU6JRWK=
MDA-MB-134-VI NWrifVFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTN3Lki3JI5O MlTlV2FPT0WU
D-283MED MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\2cGlEPTB;M{euO|khdk1? M4DMb3NCVkeHUh?=
SHP-77 MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HBZ2lEPTB;M{iuNFMhdk1? M3:4cnNCVkeHUh?=
NCI-H2227 NYfz[HhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPEN4VKSzVyPUSwMlQ6KG6P MmnPV2FPT0WU
SKM-1 Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnNZotKSzVyPUSyMlY{KG6P MoD3V2FPT0WU
L-428 M3vjNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTR|Lki2JI5O NHP6[4RUSU6JRWK=
RPMI-6666 MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XncmlEPTB;NEWuPFkhdk1? MnHIV2FPT0WU
NCI-H716 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXETWM2OD12OD64NUBvVQ>? MXXTRW5ITVJ?
DMS-79 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\HTWM2OD13MD63NUBvVQ>? M1nPV3NCVkeHUh?=
RS4-11 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7XXoVKSzVyPUWwMlg5KG6P M2rXbHNCVkeHUh?=
NCI-H720 M1jjVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4P4dmlEPTB;NUGuNVEhdk1? NIHBZoVUSU6JRWK=
MC-CAR M3;tZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37sVWlEPTB;NUGuOVIhdk1? MVnTRW5ITVJ?
TALL-1 NYPNS3FXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;Zd2lEPTB;NUOuPVEhdk1? NGH2cJJUSU6JRWK=
NCI-N87 NV;EVlBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\x[GlEPTB;NUSuNVghdk1? MXPTRW5ITVJ?
P30-OHK NYC4NG9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX6xPItVUUN3ME21OE43OSCwTR?= MmDSV2FPT0WU
LP-1 NFzPbGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnTTWM2OD14MT6yPEBvVQ>? NEDhXJZUSU6JRWK=
YT NFXDTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDRTIduUUN3ME22NU45KG6P NI\vcG5USU6JRWK=
MRK-nu-1 NGHkT5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3viZ2lEPTB;NkGuPFIhdk1? MWfTRW5ITVJ?
BT-474 NHzPPIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLSTWM2OD14NTDuUS=> NYTlWVRIW0GQR1XS
NCI-H322M Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moe1TWM2OD14Nj6xNUBvVQ>? NGjRbWdUSU6JRWK=
NCI-H128 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHFR25KSzVyPUe0Mlc4KG6P MnPpV2FPT0WU
KMS-12-PE MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\sdmo2UUN3ME23Ok4zPCCwTR?= MlywV2FPT0WU
KP-N-YS MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPQTWM2OD15Nj63OEBvVQ>? M3jHNXNCVkeHUh?=
ALL-PO M1WyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTd5Lk[2JI5O M2XhVnNCVkeHUh?=
EW-13 M{TR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{frXmlEPTB;N{euO|Yhdk1? M3f4NXNCVkeHUh?=
EW-11 NFvVXFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrVTWM2OD15OD61NkBvVQ>? M2f1cnNCVkeHUh?=
SK-N-FI NHrUSodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYH2TG9EUUN3ME24NE4zKG6P NG\2TlNUSU6JRWK=
CAL-148 MonLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rCS2lEPTB;OEGuPFQhdk1? MY\TRW5ITVJ?
RL NWHacnQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDFUYhKSzVyPUi2MlA6KG6P Mk[xV2FPT0WU
AM-38 NYniNZRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7uZ29MUUN3ME24PE4xQCCwTR?= NFjjOmNUSU6JRWK=
RH-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nZbmlEPTB;OUmuPFUhdk1? NX;YTmFNW0GQR1XS
NCI-H1770 M3;ofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFyMj60PUBvVQ>? MXjTRW5ITVJ?
SIG-M5 Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTFyNT6wOkBvVQ>? NXjNZ3J6W0GQR1XS
GR-ST M37KeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTmNJFQUUN3ME2xNVMvOzRibl2= MVLTRW5ITVJ?
ST486 NX22TnNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTFzND6wOkBvVQ>? NI\FSo1USU6JRWK=
NCI-H1650 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnlcHVRUUN3ME2xNVUvOjlibl2= NV61ZZBpW0GQR1XS
MHH-CALL-2 NWLm[ZhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFzNT63JI5O MUfTRW5ITVJ?
BV-173 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTF{Mj63NUBvVQ>? NXvkcXZ5W0GQR1XS
MC116 Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTmRZlwUUN3ME2xOFgvQDVibl2= NEXPeHNUSU6JRWK=
NCI-H524 MmrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XZR2lEPTB;MUW5MlEhdk1? MUPTRW5ITVJ?
SCLC-21H MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXNU4RpUUN3ME2xOVkvPDFibl2= NX\qZ5c4W0GQR1XS
NCI-H1304 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\NTWM2OD1zNkmuNlEhdk1? NGjaVmtUSU6JRWK=
NCI-H510A NG\PToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPXXnFKSzVyPUG4OU4{PyCwTR?= MmC1V2FPT0WU
NCI-H209 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3yyWmlEPTB;MUm2MlUzKG6P NEDnVpFUSU6JRWK=
KM-H2 M2i3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTF7Nz6wOUBvVQ>? M3fMR3NCVkeHUh?=
NCI-H1395 M1\Ve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLVTWM2OD1{MUCuNVMhdk1? M2fJT3NCVkeHUh?=
NCI-H1155 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjBRYdNUUN3ME2yN|AvOzJibl2= NUHaN4VLW0GQR1XS
COR-L279 M1\PSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHZTWM2OD1{NUKuNVchdk1? M2fmRnNCVkeHUh?=
NCI-H1299 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3KTWM2OD1{NkGuO|Ehdk1? NHnVbo5USU6JRWK=
EW-22 MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTJ4Mz63OUBvVQ>? MoPkV2FPT0WU
SK-MEL-2 MnnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnWVnNKSzVyPUK4NU46KG6P M{OxV3NCVkeHUh?=
KASUMI-1 M4C1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzkUZFKSzVyPUK4N{4xPSCwTR?= M2P1d3NCVkeHUh?=
NCI-H187 M1roNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrXPZYzUUN3ME2yPFcvODhibl2= NV7ROpRwW0GQR1XS
NCI-H2171 Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTJ6OD65NkBvVQ>? M2nsWHNCVkeHUh?=
LNCaP-Clone-FGC NIH4RZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJ7NT6yOkBvVQ>? Mn\lV2FPT0WU
NCI-H1522 M4XVcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4S4W2lEPTB;M{C3MlA2KG6P M33jPHNCVkeHUh?=
SCH MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrQNnVKSzVyPUOyNk4zOiCwTR?= NWT3dWhVW0GQR1XS
THP-1 MomyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDCTWM2OD1|MkKuOkBvVQ>? M{fETnNCVkeHUh?=
SNU-C1 MnTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTN4Mj6wPUBvVQ>? NGnM[3ZUSU6JRWK=
CA46 M4nWVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTN5Mz62N{BvVQ>? NX:yZYlQW0GQR1XS
NCI-H1963 Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L5bGlEPTB;M{i2MlE6KG6P MV3TRW5ITVJ?
DEL MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzvTWM2OD1|OUGuNlchdk1? NWW3N3hwW0GQR1XS
TUR MoH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rWRWlEPTB;M{m2MlYyKG6P M3XNWHNCVkeHUh?=
NCI-H226 NG\Ub3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LMbmlEPTB;NECzMlI{KG6P NGfQTXFUSU6JRWK=
COLO-668 NIK5e3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWH2ToZNUUN3ME20NFMvPTdibl2= NE[xe2VUSU6JRWK=
CPC-N NF\6WoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\lenpuUUN3ME20NFMvPzdibl2= NXX3SmlyW0GQR1XS
NCI-H889 NGjvdWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHScZdWUUN3ME20OlEvQTJibl2= NVPXfHN1W0GQR1XS
J-RT3-T3-5 NUfWUmtqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzwN4dHUUN3ME21N|IvPTdibl2= NXWyZmc4W0GQR1XS
MSTO-211H MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGewWZNKSzVyPUW3OE4zPiCwTR?= NVmxXoZLW0GQR1XS
SCC-15 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\LSWlEPTB;Nk[3MlQ4KG6P MYfTRW5ITVJ?
SUP-T1 NF3P[oNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTwVnlKSzVyPU[4Ok4xPCCwTR?= NI\FTFBUSU6JRWK=
DMS-153 Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\Fd5lKSzVyPUe0Ok45OyCwTR?= NYq4NIQ4W0GQR1XS
MS-1 NHfaN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7DPWFKSzVyPUe1PU41OiCwTR?= MkTsV2FPT0WU
TC-YIK NUTOcmM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULWfIhYUUN3ME23PFEvODFibl2= M3\EPHNCVkeHUh?=
RPMI-8866 M2rFSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HGeGlEPTB;MUCwOk4zQCEQvF2= M1nM[XNCVkeHUh?=
KY821 M3X0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETHSXZKSzVyPUGwN|YvODRizszN M3jDZ3NCVkeHUh?=
P31-FUJ MnfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Dl[mlEPTB;MUGxNk44PSEQvF2= MXTTRW5ITVJ?
COLO-824 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HCZWlEPTB;MUK2NU44QCEQvF2= M3ntNHNCVkeHUh?=
U-698-M MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjpb5hxUUN3ME2yNlYzNjF3IN88US=> NFvtU3ZUSU6JRWK=
TE-441-T MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vOWmlEPTB;MkWyNU44KM7:TR?= NXjafGhkW0GQR1XS
IMR-5 NVLIbWhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFv5WGJKSzVyPUO0NFkvPjJizszN NEPuUYVUSU6JRWK=
NCI-H1838 NYqxS5NRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HrXGlEPTB;NEG4Ok4{OiEQvF2= MWHTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
phospho-PERK / ATF-4; 

PubMed: 15509775     


UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against phospho-PERK, ATF-4. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. 

GRP-78 / GADD-34; 

PubMed: 15509775     


UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against GRP-78, and GADD-34. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. 

pro-caspase-12 / pro-caspase-3; 

PubMed: 15509775     


MEFs were treated with PS-341 for the indicated time periods, and the whole-cell extracts were prepared. Fifty-microgram aliquots of proteins were probed with polyclonal antibodies against caspase 12 and caspase 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin. 

pro-caspase-9; 

PubMed: 15509775     


UMSCC-23 cells were pretreated with or without Tiron for 30 min and then treated with PS-341 for the indicated time periods. The whole-cell proteins were probed with polyclonal antibodies against caspases 9 and 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin.

p-IκBα / IκBα; 

PubMed: 20335171     


PS-341 induces IκBα degradation in human lung cancer cells. The given cells lines were treated with the indicated concentrations of PS-341 for 8 h (C). After treatment, the cells were then subjected to preparation of whole-cell protein lysates and subsequent Western blot analysis. 

COX-2 / cIAP2; 

PubMed: 24085292     


NCI-H157 cells were incubated with PS-341 (50 nM) or MG132 (20 μM) for the indicated times.  Total cellular extracts were subjected to Western blot analysis for COX-2, cIAP2 and actin. 

15509775 20335171 24085292
Immunofluorescence
Vimentin; 

PubMed: 19010849     


ES-2 ovarian cancer cells were incubated with 5nM PS-341, 10 μM NK84 or the combination of both for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective). 

Ubiquitin; 

PubMed: 19010849     


IOSE-29 cells were incubated with 20nM PS-341 for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective). 

19010849
Growth inhibition assay
Cell viability ; 

PubMed: 20571067     


A, TSA enhanced the cell death induced by PS-341 in UMSCC1 cells. Cell viability was determined by the trypan blue exclusion assay. The assays were performed with triplicate samples, and the results are representative of three independent experiments (**P < 0.01). Error bars depict standard deviation. B, C and D, TSA enhanced PS-341-induced cell death in UMSCC23 (B), UMSCC9 (C), and FaDu (D). **P < 0.01.

20571067
ELISA
IL-8; 

PubMed: 24085292     


NCI-H157 cells were treated with PS-341 (10–100 nm) or TNF-α (10 ng/ml) as a positive control for 24 h. IL-8 concentrations in media were determined by ELISA. Data represent the mean ± S.D. of triplicates. **, p < 0.05 versus control cells. Results are representative of three separate experiments.

24085292
In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]

- Collapse

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]

- Collapse
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]

- Collapse
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Formulation: Saline
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4

CAS No. 179324-69-7
Storage powder
in solvent
Synonyms LDP-341, MLM341

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03993262 Not yet recruiting Drug: Bortezomib|Drug: Placebo Autoimmune Encephalitis Jena University Hospital October 1 2019 Phase 2
NCT00425503 Completed Drug: PS-341 (bortezomib) Prostate Neoplasms Baylor College of Medicine|Millennium Pharmaceuticals Inc. December 2001 Phase 2
NCT00025376 Completed Drug: PS-341|Procedure: Tumor Biopsy Kidney Cancer University of Chicago|National Cancer Institute (NCI) October 2001 Phase 2
NCT00237627 Completed Drug: PS-341|Drug: Doxil|Drug: Velcade Breast Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Ovarian Cancer|Unspecified Adult Solid Tumor Protocol Specific UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) May 2001 Phase 1|Phase 2
NCT00006773 Terminated Drug: bortezomib Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor National Cancer Institute (NCI) May 2001 Phase 1
NCT00373906 Completed Drug: Bortezomib (Velcade) MALT Lymphoma Medical University of Vienna Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • Answer:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID